相关实验视频

Updated: Jun 26, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

骨髓纤维化药物治疗的进展:目前的情况是什么?

Mario Tiribelli^1,2, Gianluca Morelli¹, Massimiliano Bonifacio³

¹Division of Hematology and Stem Cell Transplant, Azienda Sanitaria Universitaria Friuli Centrale,Ospedale S. M. Misericordia, Udine, Italy.

Expert opinion on pharmacotherapy

|May 13, 2024

概括

雅努斯酶抑制剂 (JAKi) 已经推进了髓纤维化 (MF) 治疗,但单一治疗很少改变疾病的进展. 新药有希望,需要个性化治疗策略,将JAKi与新药结合起来,以获得更好的结果.

科学领域:

血液学血液学血液学
在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

十多年前,第一个Janus激酶抑制剂 (JAKi) 卢克索利提尼布 (ruxolitinib) 彻底改变了髓纤维化 (MF) 治疗方法,主要是改善的大小和症状负担.
目前,费德拉提尼布,帕克里提尼布和莫梅洛提尼布可用于未经治疗的和抗鲁克索利提尼布的MF患者的JAK抑制剂.
许多新型疗法正在研究中,无论是单一治疗还是与现有的JAK抑制剂结合使用.

研究的目的:

审查ruxolitinib的长期数据以及MF中fedratinib,pacritinib和momelotinib的最近临床试验证据.
检查新兴的非JAK抑制剂疗法,包括BET抑制剂 (pelabresib) 和BCL抑制剂 (navitoclax).
讨论针对贫血的药物,这是影响MF生存的关键因素.

主要方法:

在骨髓纤维化症中使用鲁克索利提尼布治疗的长期数据的审查.
对费德拉提尼布,帕克里提尼布和莫梅洛提尼布作为一线或二线MF治疗的最近临床试验数据的分析.
评估新药数据,如BET抑制剂和BCL抑制剂,以及针对贫血的治疗方法.

主要成果:

单独使用JAK抑制剂证明了临床疗效,但很少改变髓纤维化自然过程.
新兴的新药显示出希望,但广泛的长期数据仍然有限.
贫血仍然是MF患者减少生存的重要决定因素.

结论:

骨髓纤维化治疗正在向个性化策略发展.
临床医生需要根据患者的特征选择合适的JAK抑制剂.
预计使用JAK抑制剂和新型非JAK抑制剂的联合治疗将推动疾病的修饰.

关键词:

雅克抑制剂的使用骨髓纤维化骨髓纤维化贫血的改善贫血的改善组合疗法是一种组合疗法.药物疗法 (pharamacotherapy) 是一种药物疗法.

更多相关视频

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Differentiation of Common Myeloid Progenitor Cells

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

Introduction to Fibroblasts

Introduction to Fibroblasts

Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...